1,080 material Form 8-K filings that 839 companies we cover made with the SEC in May 2025, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Equifax said Todd Horvath, head of its U.S. Information Solutions unit, will leave the company effective June 1, 2025, and that CEO Mark Begor will lead USIS until a successor is found. The filing also discloses a separation package including a $2.9 million lump-sum severance payment and about $3.2 million in cash for unvested new-hire equity, which is a cost to the company.
Todd Horvath departs as EVP and President, U.S. Information Solutions, effective June 1, 2025
CEO Mark Begor will lead USIS while the company searches for a successor
Lump-sum severance of $2.9 million, about two years of annual cash compensation before taxes and withholdings
About $3.2 million in cash for the unvested portion of his new-hire "make whole" equity award; prorated 2025 incentive payable in Q1 2026
Proto Labs entered a new consulting agreement with Robert Bodor, who ceased to be President and CEO effective May 20, 2025. Under the agreement dated May 28, 2025, Bodor will provide transitional services for a monthly fee of $5,000 through November 11, 2025, subject to him signing a general waiver and release of claims.
Monthly consulting fee of $5,000, with the term running through November 11, 2025
Agreement is conditioned on Bodor signing and not rescinding a general waiver and release of claims
Bodor keeps vested stock options until the agreement ends or he exercises them; unvested options are forfeited, and vested options may be exercised for three months after termination or expiration
Coda Octopus Group, Inc. disclosed that G. Tyler Runnels resigned from its Board of Directors on May 27, 2025. The company said there were no disagreements between it and Mr. Runnels. The filing does not give a reason for the resignation or name a replacement.
Director G. Tyler Runnels resigned from the Board on May 27, 2025.
The company states there were no disagreements between it and Mr. Runnels.
The filing includes only the Inline XBRL cover page exhibit and does not name a successor.
Neurocrine Biosciences said Sanjay Keswani, M.D. will succeed Eiry W. Roberts, M.D. as Chief Medical Officer effective June 2, 2025. Dr. Roberts, who has held the role for seven years, will stay on as Strategic Advisor to the CEO through December 31, 2025 under an amended employment agreement with a $731,400 base salary.
Sanjay Keswani, M.D. succeeds Eiry W. Roberts, M.D. as Chief Medical Officer effective June 2, 2025
Dr. Roberts becomes Strategic Advisor to the CEO through December 31, 2025, with a $731,400 annual base salary
Dr. Roberts's target bonus is 60% of base pay for calendar year 2025; severance and outstanding equity awards carry over
VF's board appointed Michael E. Phillips as Vice President, Chief Accounting Officer, effective June 1, 2025. He replaces Bryan H. McNeill, who notified the company on May 27, 2025 that he is retiring after nearly 30 years of service. The filing describes a planned leadership change in the finance function and does not mention any financial results or guidance.
Michael E. Phillips, 52, has been VP, Enterprise Financial Reporting Controller since September 2022 and joined VF in June 2010.
Phillips is a Certified Public Accountant and previously led audit and financial due diligence engagements over 15 years.
Bryan H. McNeill is retiring after nearly 30 years of service; his resignation as Chief Accounting Officer is effective June 1, 2025.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.